Vpriv® (velaglucerase alfa)

Vpriv (velaglucerase alfa) is covered only for FDA‑approved treatment of Type 1 Gaucher disease and is not supported for other diagnoses or Gaucher types. Coverage requires documented diagnosis (deficient β‑glucocerebrosidase activity in leukocytes/fibroblasts or molecular GBA mutation), prescription by or documented consultation with a geneticist, endocrinologist, metabolic disorder or lysosomal storage disorder specialist, dosing 60 U/kg IV no more frequently than every 2 weeks, and approval is limited to one year.

"Approval duration limited to 1 year."

Sign up to see full coverage criteria, indications, and limitations.